ARVINAS, INC. Capital Expenditures
ARVINAS, INC. (ARVN) reported Capital Expenditures of $1.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-04
- ARVINAS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $200.00K, a 83.33% decline year-over-year.
- ARVINAS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $1.30M, a 225.00% increase year-over-year.
- ARVINAS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $200.00K, a 33.33% decline year-over-year.
- ARVINAS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $100.00K, a 85.71% decline year-over-year.
- ARVINAS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $1.90M, a 5.56% increase from fiscal 2024.
- ARVINAS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $1.80M, a 37.93% decline from fiscal 2023.
- ARVINAS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $2.90M, a 57.35% decline from fiscal 2022.
- ARVINAS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $6.80M, a 44.68% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.50M 10-Q · filed 2026-08-04 | $1.70M derived: sum of 3 quarters · filed 2026-08-04 | $1.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-11 | $1.50M derived: sum of 2 quarters · filed 2026-05-11 | $1.60M derived: sum of 3 quarters · filed 2026-05-11 | $2.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $300.00K derived: sum of 2 quarters · filed 2026-02-24 | $1.50M derived: sum of 3 quarters · filed 2026-08-04 | $1.90M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.30M derived: sum of 2 quarters · filed 2026-08-04 | $1.70M 10-Q · filed 2025-11-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.60M 10-Q · filed 2026-08-04 | $1.90M derived: sum of 3 quarters · filed 2026-08-04 | $2.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-11 | $700.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.40M derived: sum of 3 quarters · filed 2026-05-11 | $2.10M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.70M derived: sum of 3 quarters · filed 2026-02-24 | $1.80M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.40M derived: sum of 2 quarters · filed 2025-11-05 | $1.50M 10-Q · filed 2025-11-05 | $1.60M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $800.00K 10-Q · filed 2025-08-06 | $900.00K derived: sum of 3 quarters · filed 2026-02-24 | $2.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-01 | $200.00K derived: sum of 2 quarters · filed 2026-02-24 | $1.30M derived: sum of 3 quarters · filed 2026-02-24 | $1.90M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.20M derived: sum of 2 quarters · filed 2026-02-24 | $1.80M derived: sum of 3 quarters · filed 2026-02-24 | $2.90M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $1.70M derived: sum of 2 quarters · filed 2024-10-30 | $2.80M 10-Q · filed 2024-10-30 | $3.90M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $1.70M 10-Q · filed 2024-07-30 | $2.80M derived: sum of 3 quarters · filed 2025-02-11 | $5.00M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-07 | $2.20M derived: sum of 2 quarters · filed 2025-02-11 | $4.40M derived: sum of 3 quarters · filed 2025-02-11 | $5.80M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $3.30M derived: sum of 2 quarters · filed 2025-02-11 | $4.70M derived: sum of 3 quarters · filed 2025-02-11 | $6.80M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.60M derived: sum of 2 quarters · filed 2023-11-07 | $5.70M 10-Q · filed 2023-11-07 | $7.60M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.50M 10-Q · filed 2023-08-08 | $5.40M derived: sum of 3 quarters · filed 2024-02-27 | $6.70M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $2.10M 10-Q · filed 2023-05-05 | $4.00M derived: sum of 2 quarters · filed 2024-02-27 | $5.30M derived: sum of 3 quarters · filed 2024-02-27 | $5.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.20M derived: sum of 2 quarters · filed 2024-02-27 | $3.70M derived: sum of 3 quarters · filed 2024-02-27 | $4.70M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.80M derived: sum of 2 quarters · filed 2022-11-09 | $2.80M 10-Q · filed 2022-11-09 | $2.81M 10-Q · filed 2021-11-03 | $4.61M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.50M 10-Q · filed 2022-08-04 | $1.46M 10-Q · filed 2021-08-05 | $3.31M derived: sum of 3 quarters · filed 2023-02-23 | $4.71M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-05 | $989.90K 10-Q · filed 2021-05-04 | $2.81M derived: sum of 2 quarters · filed 2023-02-23 | $4.21M derived: sum of 3 quarters · filed 2023-02-23 | $6.04M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $3.21M derived: sum of 2 quarters · filed 2023-02-23 | $5.04M derived: sum of 3 quarters · filed 2023-02-23 | $6.40M 10-K · filed 2023-02-23 | $6.45M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $3.23M derived: sum of 2 quarters · filed 2021-11-03 | $4.59M 10-Q · filed 2021-11-03 | $6.44M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.19M 10-Q · filed 2021-08-05 | $5.03M derived: sum of 3 quarters · filed 2022-02-28 | $6.22M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $1.36M 10-Q · filed 2021-05-04 | $3.21M derived: sum of 2 quarters · filed 2022-02-28 | $4.39M derived: sum of 3 quarters · filed 2022-02-28 | $7.28M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.03M derived: sum of 2 quarters · filed 2022-02-28 | $5.92M derived: sum of 3 quarters · filed 2022-02-28 | $6.30M 10-K · filed 2022-02-28 | $6.24M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.07M derived: sum of 2 quarters · filed 2020-11-05 | $4.46M 10-Q · filed 2020-11-05 | $5.08M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $3.27M 10-Q · filed 2020-08-04 | $3.89M derived: sum of 3 quarters · filed 2021-03-01 | $4.83M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $380.64K 10-Q · filed 2020-04-28 | $1.00M derived: sum of 2 quarters · filed 2021-03-01 | $1.94M derived: sum of 3 quarters · filed 2021-03-01 | $2.57M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $621.55K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.56M derived: sum of 2 quarters · filed 2021-03-01 | $2.19M derived: sum of 3 quarters · filed 2021-03-01 | $2.83M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $938.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $1.57M derived: sum of 2 quarters · filed 2019-11-04 | $2.21M 10-Q · filed 2019-11-04 | $2.64M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | $631.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $1.27M 10-Q · filed 2019-08-05 | $1.70M derived: sum of 3 quarters · filed 2019-08-05 | |||||
| 2018-03-31 | $638.64K 10-Q · filed 2019-05-09 | $1.07M derived: sum of 2 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $434.57K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $1.01M 10-K · filed 2019-03-26 | ||||||
| 2017-09-30 | $577.86K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |